DELIVERY ORDER
Active75A50126F61015
Department of Health and Human Services › Office of Assistant Secretary for Preparedness and Response › BARDA - ASPR / DAAPPO / BARDA DCMA
$42.8M
obligated · signed 7 days ago
FORMULATION AND FILLING OF MF59-ADJUVANTED CELL-BASED A/HENAN/4-10CNIC/2022 (H3N8)-LIKE VACCINE AND CLINICAL TRIAL IMPLEMENTATION
Performance timeline
Start
Sep 30, 2026
End
Mar 29, 2030
with all options
Loading status
Estimated start: Mar 29, 2029
SEQIRUS INC
Contract 75A50126F61015
UEI
Z6N1LJ2RD6E3
Parent Company
SEQIRUS INC
Capabilities & Certifications
Headquarters Location
Congressional District: 04
Current Obligation
$42,769,479
Base + Exercised Options
$42,769,479
Total Ceiling Value
$42,769,479
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING
PSC
DRUGS AND BIOLOGICALS
Place of Performance
Congressional District: 04
Awarding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Funding Agency
Top-tier agency
Office of Assistant Secretary for Preparedness and Response
Sub-tier agency
BARDA - ASPR / DAAPPO / BARDA DCMA
Office
Contract Vehicle
75A50122D00004
IDCDepartment of Health and Human Services
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.